Thomas Wilder Sells 372 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Key Points

• Thomas Wilder, a director at Penumbra, Inc., sold 372 shares of the company on August 12th for approximately $89,339.52, resulting in a 50% decrease in his ownership of the stock.
• Penumbra's stock is currently valued at $257.67 with a market capitalization of $10.05 billion, and the company recently reported a revenue increase of 13.4% over the same quarter last year.
• Analysts have generally given Penumbra a moderate buy rating, with a consensus target price of $300.47, indicating potential for future price appreciation.

Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Thomas Wilder sold 372 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $240.16, for a total transaction of $89,339.52. Following the completion of the sale, the director owned 372 shares in the company, valued at approximately $89,339.52. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Penumbra Stock Performance

NYSE PEN traded up $9.12 during trading on Wednesday, hitting $257.67. 582,380 shares of the company's stock traded hands, compared to its average volume of 516,493. The stock has a market capitalization of $10.05 billion, a price-to-earnings ratio of 70.81, a PEG ratio of 2.24 and a beta of 0.40. Penumbra, Inc. has a 12-month low of $181.13 and a 12-month high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75. The business has a 50 day moving average of $246.26 and a 200-day moving average of $265.87.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.81 by $0.05. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The business had revenue of $339.46 million for the quarter, compared to the consensus estimate of $327.37 million. During the same period in the prior year, the firm earned $0.64 earnings per share. The company's revenue was up 13.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Penumbra

Institutional investors and hedge funds have recently modified their holdings of the company. LPL Financial LLC increased its position in shares of Penumbra by 4.0% in the fourth quarter. LPL Financial LLC now owns 9,486 shares of the company's stock worth $2,253,000 after purchasing an additional 368 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Penumbra by 3.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 60,485 shares of the company's stock worth $14,364,000 after acquiring an additional 2,033 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Penumbra by 830.2% in the fourth quarter. Russell Investments Group Ltd. now owns 19,989 shares of the company's stock worth $4,747,000 after purchasing an additional 17,840 shares during the last quarter. Cerity Partners LLC grew its holdings in shares of Penumbra by 66.1% in the fourth quarter. Cerity Partners LLC now owns 5,999 shares of the company's stock worth $1,400,000 after purchasing an additional 2,387 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Penumbra in the fourth quarter worth approximately $5,976,000. 88.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. UBS Group set a $335.00 target price on Penumbra and gave the stock a "buy" rating in a report on Wednesday, July 30th. Citigroup lowered their price objective on shares of Penumbra from $320.00 to $285.00 and set a "neutral" rating for the company in a research note on Wednesday, July 9th. Morgan Stanley lifted their price target on shares of Penumbra from $260.00 to $266.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Canaccord Genuity Group set a $350.00 price objective on Penumbra and gave the stock a "buy" rating in a report on Wednesday, July 30th. Finally, William Blair raised shares of Penumbra to a "strong-buy" rating in a report on Friday, July 18th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Penumbra presently has an average rating of "Moderate Buy" and a consensus target price of $300.47.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.